目的 探討腦康泰片聯(lián)合多巴絲肼治療帕金森病的臨床療效。方法 納入2022年7月—2025年2月徐州市中心醫(yī)院接受診治的120例帕金森病患者，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，各60例。對(duì)照組口服多巴絲肼片，初始劑量62.5 mg/次，3次/d，每周遞增125 mg，直至最終有效劑量，最大劑量≤250 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服腦康泰片，3片/次，3次/d。兩組療程12周。評(píng)估兩組臨床療效。比較治療前后兩組量表評(píng)分[39項(xiàng)帕金森病生活質(zhì)量問(wèn)卷（PDQ-39）評(píng)分、帕金森病睡眠量表-2（PDSS-2）評(píng)分、日常生活能力評(píng)定量表（ADL）評(píng)分]及血清腦源性神經(jīng)營(yíng)養(yǎng)因子（BDNF）、同型半胱氨酸（Hcy）、白細(xì)胞介素-6（IL-6）、谷胱甘肽過(guò)氧化物酶（GSH-Px）、丙二醛（MDA）水平。結(jié)果 治療組總有效率是93.33%，高于對(duì)照組的80.00%（P＜0.05）。治療后，兩組統(tǒng)一帕金森病評(píng)定量表（UPDRS）-Ⅰ評(píng)分、UPDRS-Ⅱ評(píng)分、UPDRS-Ⅲ評(píng)分、UPDRS-Ⅳ評(píng)分、總評(píng)分均顯著降低（P＜0.05）；治療后，治療組患者UPDRS各亞量表評(píng)分及總評(píng)分較對(duì)照組更低（P＜0.05）。治療后，兩組患者PDQ-39、PDSS-2評(píng)分和血清Hcy、IL-6、MDA都低于同組治療前（P＜0.05）；治療組都低于對(duì)照組（P＜0.05）。治療后，兩組ADL評(píng)分和血清BDNF、GSH-Px都顯著升高（P＜0.05），并以治療組增加為甚（P＜0.05）。結(jié)論 帕金森病應(yīng)用腦康泰片聯(lián)合多巴絲肼治療安全性較好，不僅能顯著提升患者的日?；顒?dòng)能力、睡眠狀況及生活品質(zhì)，還能有效抑制炎癥反應(yīng)和氧化損傷，對(duì)神經(jīng)元具有保護(hù)效應(yīng)，利于臨床癥狀緩解和病情控制。

Objective To investigate the clinical efficacy of Naokangtai Tablets combined with levodopa and benserazide in the treatment of Parkinson’s disease (PD). Methods A total of 120 PD patients treated at Xuzhou Central Hospital from July 2022 to February 2025 were enrolled and divided into two groups according to the random number table method, with 60 cases in each group. The control group was po administered with Levodopa and Benserazide Hydrochloride Tablets at an initial dose of 62.5 mg/time, 3 times/d, with a weekly increment of 125 mg until the final effective dose (maximum dose ≤ 250 mg/time, 3 times/d). The treatment group was additionally given Naokangtai Tablets (3 tablets/time, 3 times/d) on the basis of the control group. Both groups were treated for 12 weeks. The clinical efficacy was evaluated, and changes in scale scores [39-item Parkinson’s Disease Questionnaire (PDQ-39), Parkinson’s Disease Sleep Scale-2 (PDSS-2), Activity of Daily Living (ADL) scale] and serum levels of brain-derived neurotrophic factor (BDNF), homocysteine (Hcy), interleukin-6 (IL-6), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA) were compared between the two groups before and after treatment. Results The total effective rate of the treatment group was 93.33%, which was higher than that of the control group (80.00%, P < 0.05). After treatment, both groups showed significant reductions in Unified Parkinson’s Disease Rating Scale (UPDRS) subscale scores (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and total score (P<0.05), with the treatment group exhibiting lower scores in all UPDRS subscales and total score compared to the control group (P < 0.05). Post-treatment, PDQ-39, PDSS-2 scores, and serum levels of Hcy, IL-6, and MDA were significantly decreased in both groups compared to pre-treatment (P< 0.05), and these indices were further reduced in the treatment group versus the control group (P< 0.05). Additionally, ADL scores and serum levels of BDNF and GSH-Px were significantly increased in both groups after treatment (P< 0.05), with more pronounced elevations observed in the treatment group (P< 0.05). Conclusion The combination of Naokangtai Tablets and levodopa and benserazide is safe and effective for PD. It not only significantly improves patients’ daily activity ability, sleep quality, and quality of life but also effectively inhibits inflammatory responses and oxidative damage, exerts neuroprotective effects, and contributes to the alleviation of clinical symptoms and disease control.

R971

徐州市衛(wèi)健委2022年度醫(yī)學(xué)科技創(chuàng)新項(xiàng)目（XWKYHT20220162）